Premium
Plasma Proteomic Signatures in Early Chronic Obstructive Pulmonary Disease
Author(s) -
Baralla Angela,
Fois Alessandro G.,
Sotgiu Elisabetta,
Zinellu Elisabetta,
Mangoni Arduino A.,
Sotgia Salvatore,
Zinellu Angelo,
Pirina Pietro,
Carru Ciriaco
Publication year - 2018
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201700088
Subject(s) - haptoglobin , ceruloplasmin , copd , apolipoprotein b , medicine , transthyretin , inflammation , proteome , lipoprotein , pulmonary disease , apolipoprotein a1 , oxidative stress , blood proteins , immunology , pathology , biology , bioinformatics , cholesterol
Purpose Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2‐DE followed by MALDI TOF‐MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate. Experimental design Blood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age‐ and sex‐matched control subjects. Proteome analysis was based on 2D‐Page followed by MALDI‐TOF MS identifications. Validation was made on two significant proteins by western blotting. Results The analyses revealed 29 between‐group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha‐1 chain C), blood coagulation and complement pathways (prothrombin, complement 4‐B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A‐I, and apolipoprotein E). Conclusion and clinical relevance These results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.